# Phase III multidisciplinary exercise-based rehabilitation is associated with fewer hospitalizations due to adverse cardiovascular events in coronary artery disease patients

Dominique Hansen, PhD, FESC1-3; Wout Mathijs, MSc1; Yannah Michiels, MSc1; Kim Bonné, MSc2; Toon Alders, MSc2; Ann Hermans, BSc2; Katrien Copermans, MSc2; Hans Swinnen, MSc2; Vincent Maris, MSc2; Ine Timmermans, MSc2; Johan Vaes, MD2; Emmanuela Govaerts, MD2, Veerle Reenaers, MD2; Ines Frederix, MD, PhD2-4; Patrick J Doherty, PhD5; Paul Dendale, MD, PhD, FESC2,3

1. REVAL – Rehabilitation Research Center, Faculty of Rehabilitation Sciences, Hasselt University, Diepenbeek, Belgium

2. Jessa Hospital, Heart Center Hasselt, Hasselt, Belgium

3. BIOMED - Biomedical Research Center, Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium

4. Faculty of Medicine and Health Sciences, Antwerp University,

Antwerp, Belgium

5. Department of Health Sciences, University of York, York, UK

Keywords: cardiac rehabilitation, coronary artery disease, hospitalization, mortality

Full-text word count: 996

Contact details:

Prof. Dominique Hansen

REVAL – Rehabilitation Research Center

Faculty of Rehabilitation Sciences

Hasselt University

Agoralaan, Building A,

3590 Diepenbeek, Belgium

e-mail: Dominique.hansen@uhasselt.be

Phone: 0032 497875866

Multidisciplinary exercise-based cardiovascular rehabilitation (CR) leads to significant reductions in mortality and risk for adverse cardiovascular events in coronary artery disease (CAD) patients.1 As a result, CR is a class 1A intervention.2 However, in many countries, the number of supervised CR sessions is limited due to logistic issues or reimbursement policies. The peak oxygen uptake of CAD patients however continues to increase when the participation in CR is prolonged,3 and additional improvements in blood pressure, lipid profile, and glycemic control are noticed as a result of prolonged CR.4 We hypothesize that CAD patients may benefit from prolonged (phase III) CR programs, evidenced through less hospitalization and/or the prevention of premature death, which has been noticed in heart failure patients.5 The aim of this study is, therefore, to evaluate if supervised phase III CR in CAD patients leads to greater reductions in hospitalizations, due to adverse cardiovascular events, and mortality, when compared to a standard 3-month supervised CR program.

In this retrospective study, files from patients who participated in a multidisciplinary exercise-based CR program at Jessa Hospital, Hasselt, Belgium, starting from January 2013 up to January 2017, were consulted. This study was approved by the Jessa Hospital medical ethics committee. Patients with the primary diagnosis of CAD (based on angiography during an elective investigation, hospital admission because of an acute coronary syndrome, or significant ST-segment depression during exercise testing) with or without heart failure, implantable cardioverter defibrillator and/or pacemaker, and who completed a 3-month CR program (with the completion of at least 30 supervised exercise training sessions) within three months, without the re-occurrence of cardiovascular re-events within this time frame, were selected. From those patients, some continued their supervised CR, thus leading to two subgroups: a comparison group (who did not further participate in supervised CR) vs. an intervention group (who further participated in supervised CR).

At the entry of CR, age, sex, medication, cardiovascular risk factors (blood pressure, body mass index, blood lipid profile (total, high- and low-density lipoprotein cholesterol), blood glucose and glycated hemoglobin, smoking behavior), indication for CR, peak workload capacity (Wpeak), and peak oxygen uptake (VO2peak) were recorded/assessed. The groups were case-matched at the entry of CR for body mass index, age, and sex. Hereafter, a 3-month multidisciplinary CR was started (patients were also offered consultations with a psychologist, dietician, and/or social nurse when indicated). The exercise sessions (2-3/week) consisted of 40-60 min aerobic exercises such as treadmill walking, cycling, and arm cranking.6,7 The exercise intensity was based on the heart rate and workload, set between the first and second ventilatory threshold, and was gradually increased during the CR program. Low-to-moderate resistance training was also implemented at an intensity and frequency tailored to each patient. After three months of CR, the patients from the intervention group were supported to exercise on other modalities as well (e.g. rowing, stepping) and without strict monitoring of the exercise intensity. Next, the patient records from Jessa Hospital were investigated for the re-occurrence of hospitalization due to adverse cardiovascular events (symptomatic cardiac arrhythmias (palpitations, syncope), excessive dyspnoea or orthopnoea, angina pectoris, acute myocardial infarction)) or revascularization (by percutaneous coronary intervention or bypass surgery), or death over a maximal possible follow-up duration, starting from the completion of the 3-month CR. All patients were followed by cardiologists from Jessa Hospital, so any adverse event was reported in these hospital records. In case of an adverse event with (urgent) admission to another hospital, the report of this admission was sent to and stored by, Jessa Hospital. By SAS JMP® unpaired t-tests were used to compare continuous variables between the groups, or chi-square tests for nominal data, all with Bonferroni corrections for multiple comparisons (to avoid type 1a errors). Kaplan-Meier curves were created to examine the time to the first hospitalization and a log-rank test was applied for comparison between the groups. A p-value <0.05 (two-tailed) was considered statistically significant.

At the entry of CR, the groups were statistically comparable (Table 1) on baseline variables, except for the intake of diuretics. The intake of diuretics in CAD patients is associated with an elevated mortality, and thus not in favour of the intervention group.8 As a result of three months of CR, the patients experienced significant but equal increments in Wpeak (from 127±10W to 148±11W in the comparison group, from 120±10W to 137±11W in the intervention group) and VO2peak (from 1526±101ml/min to 1654±105ml/min in the comparison group, from 1445±100ml/min to 1654±124ml/min in the intervention group). After this phase, only the intervention group continued the multidisciplinary CR program, in which the follow-up duration was not different between the groups (36.7±3.5 vs. 42.1±4.7 months in the comparison vs. intervention group) and medication prescription did not change (data not shown). In total, 42±1 vs. 148±31 supervised exercise training sessions were completed in the comparison vs. intervention group (p<0.05). CAD patients in the intervention group had significantly fewer hospitalizations than in the comparison group (hazard ratio (HR): 2.31 (95% CI=1.42-3.76)). The intervention group also had shorter periods of hospitalization (by ±62%, Table 1, Figure 1). These observations align with previous studies, in which significantly greater improvements in cardiovascular risk and physical fitness were noticed as a result of prolonged CR.3,4 Mortality was however not different between the groups, possibly related to the low rate of mortality generally at 4.6% in the total group (Table 1). The observed clinical benefits in the present study are hypothesized to be related to prolonged supervised exercise training, greater adherence to medication prescription, healthy nutrition guidelines, and better psychological coping,9 next to the direct availability of healthcare professionals to address symptoms/questions. As a result, this study suggests that supervised multidisciplinary phase III CR is of benefit to CAD patients. This study was limited by a small, single site, retrospective design with an inability to control for potential confounding variables. On the plus side the CAD population was strongly representative, of routine clinical practice, in terms of age and comorbidity. An explanation for the difference in diuretics intake between groups cannot be provided.

**Authorship**

DH, WM, and YM contributed to the conception or design of the work. DH, WM, YM, KB, TA, AH, KC, HS, VM, IT, JV, and VR contributed to the acquisition, analysis, or interpretation of data for the work. DH AND PJD drafted the manuscript. WM, YM, KB, TA, AH, KC, HS, VM, IT, JV, EG, VR, IF, PJD, and PD critically revised the manuscript. All gave final approval and agree to be accountable for all aspects of work ensuring integrity and accuracy.

**Conflicts of interest**

The authors declared no potential conflicts of interest concerning the research, authorship, and/or publication of this article.

**Funding**

This study was supported by an unrestricted grant from Hartcentrum Hasselt, vzw.

# **References**

1. Salzwedel A, Jensen K, Rauch B, et al. Effectiveness of comprehensive cardiac rehabilitation in coronary artery disease patients treated according to contemporary evidence based medicine: Update of the Cardiac Rehabilitation Outcome Study (CROS-II). *Eur J Prev Cardiol* 2020; e-pub ahead of print, doi: 10.1177/2047487320905719.
2. Ambrosetti M, Abreu A, Corrà U, et al. Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. *Eur J Prev Cardiol* 2020; e-pub ahead of print, doi: 10.1177/2047487320913379.
3. Hamm LF, Kavanagh T, Campbell RB, et al. Timeline for peak improvements during 52 weeks of outpatient cardiac rehabilitation. *J Cardiopulm Rehabil* 2004; 24: 374-80.
4. Reich B, Benzer W, Harpf H, et al. Efficacy of extended, comprehensive outpatient cardiac rehabilitation on cardiovascular risk factors: A nationwide registry. *Eur J Prev Cardiol* 2020: 27: 1026-33.
5. Belardinelli R, Georgiou D, Cianci G, et al. 10-year exercise training in chronic heart failure: a randomized controlled trial. *J Am Coll Cardiol* 2012; 60: 1521-8.
6. Hansen D, Eijnde BO, Roelants M, et al. Clinical benefits of the addition of lower extremity low-intensity resistance muscle training to early aerobic endurance training intervention in patients with coronary artery disease: a randomized controlled trial. *J Rehabil Med* 2011; 43: 800-7.
7. Boujemaa H, Verboven K, Hendrikx M, et al. Muscle wasting after coronary artery bypass graft surgery: impact on post-operative clinical status and effect of exercise-based rehabilitation. *Acta Cardiol* 2019; e-pub ahead of print, doi: 10.1080/00015385.2019.1598035.
8. Schartum-Hansen H, Løland KH, Svingen GF, et al. Use of Loop Diuretics is Associated with Increased Mortality in Patients with Suspected Coronary Artery Disease, but without Systolic Heart Failure or Renal Impairment: An Observational Study Using Propensity Score Matching. *PLoS One* 2015; 10: e0124611.
9. Kotseva K, Wood D, De Bacquer D; EUROASPIRE investigators. Determinants of participation and risk factor control according to attendance in cardiac rehabilitation programmes in coronary patients in Europe: EUROASPIRE IV survey. *Eur J Prev Cardiol* 2018; 25: 1242-51.

**Tables and figures**

**Table 1** Characteristics at the entry of CR and outcomes during follow-up

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable**  | **Comparison** **n = 87** | **Intervention** **n = 87** | **p-value** |
| **Age (years)** | 69 (2) | 70 (2) | NS |
| **Sex (n)** | 70 (♂) | 70 (♂) | NS |
| **Weight (kg)**  | 79 (3) | 80 (3) | NS |
| **Height (cm)** | 172 (2) | 171 (2) | NS |
| **Cardiovascular diseases, n (%)** |  |  |  |
| *Myocardial infarction* | 32 (37) | 39 (45) | NS |
| *CAD/AMI treated by:*  |  |  |  |
| *CABG* | 16 (19) | 22 (24) | NS |
| *ENDO ACAB* | 11 (13) | 6 (7) | NS |
| *PCI* | 59 (68) | 60 (69) | NS |
| *Cardiovascular co-morbidities:**Heart failure* | 6 (7) | 6 (7) | NS |
| *Valve disease* | 1 (1) | 7 (8) | NS |
| *Pacemaker* | 4 (5) | 5 (6) | NS |
| *ICD*  | 3 (3) | 8 (9) | NS |
| **Medication, n (%)** |  |  |  |
| *Beta-blocker* | 71 (82) | 65 (75) | NS |
| *Calcium channel blocker* | 11 (12) | 17 19) | NS |
| *ACE inhibitor* | 41 (47) | 43 (49) | NS |
| *Angiotensin II receptor antagonist* | 5 (6) | 0 (0) | NS |
| *Diuretic* | 11 (13) | 29 (33) | 0.044 |
| *Antithrombotic* | 81 (93) | 84 (97) | NS |
| *Nitrate* | 13 (15) | 19 (22) | NS |
|  *Statin* | 83 (95) | 75 (86) | NS |
|  *Fibrate* | 1 (1) | 3 (3) | NS |
|  *Metformin* | 5 (6) | 7 (8) | NS |
|  *Sulfonylurea* | 2 (2) | 0 (0) | NS |
|  *DPP4 inhibitor* | 1 (1) | 0 (0) | NS |
|  *Incretin* | 0 (0) | 1 (1) | NS |
|  *Insulin* | 3 (3) | 4 (5) | NS |
| **Cardiovascular risk factors** |  |  |  |
| *Total cholesterol (mg/dl)* | 170 (11) | 159 (9) | NS |
| *Triglycerides (mg/dl)* | 152 (22) | 135 (12) | NS |
| *LDL (mg/dl)* | 96 (9) | 89 (8) | NS |
| *HDL (mg/dl)* | 47 (3) | 45 (3) | NS |
| *Fasting blood glucose (mg/dl)* | 110 (4) | 111 (11) | NS |
| *HbA1c (mmol/mol)* | 38 (1) | 39 (3) | NS |
| *Systolic BP (mmHg)* | 143 (6) | 144 (8) | NS |
| *Diastolic BP (mmHg)* | 82 (5) | 81 (3) | NS |
| *Smoking, n (%)* | 29 (33) | 22 (25) | NS |
| *BMI (kg/m²)* | 26.5 (0.9) | 27.4 (0.8) | NS |
| **Exercise capacity** |  |  |  |
| *Peak workload capacity (W)* |  127 (10) |  120 (10) | NS |
| *Peak oxygen uptake (ml/min)* | 1526 (101) |  1445 (100) | NS |
| **Outcomes during follow-up** |  |  |  |
| Patients hospitalized, n (%) | 43 (49) |  30 (34) | 0.046 |
| Total hospitalization days/patient | 0.91 (0.3) | 0.55 (0.2) | NS |
| Total hospitalization days/patient/month | 0.028 (0.01) | 0.013 (0.005) | 0.0027 |
| Time to first hospitalization (days) | 532 (156) | 1038 (446) | 0.0020 |
| Days/hospitalization per patient  | 2.66 (1.02) | 1.41 (0.56) | NS |
| Days/hospitalization per patient/month | 0.08 (0.03) | 0.03 (0.01) | 0.029 |
| Death (n patients) | 2 | 6 | NS |

Categorical variables are expressed as proportion (%, n). Continuous variables are expressed as mean (SD). ACE: angiotensin-converting enzyme; BMI: body mass index; DPP4: dipeptidyl peptidase-4; BP: blood pressure; LDL: low-density lipoprotein; HDL: high-density lipoprotein; HbA1c: glycated haemoglobin; ICD: implantable cardioverter defibrillator; CABG: coronary artery bypass grafting; AMI, acute myocardial infarction; PCI: percutaneous coronary intervention; ENDO ACAB: endoscopic atraumatic coronary artery bypass; CAD: coronary artery disease.

**Figure Legend**

**Figure 1** Kaplan-Meier curve representing time to the first hospitalization as a result of three months of CR vs. phase III CR

Significantly fewer hospitalizations were noticed in CAD patients who prolonged the exercise-based CR beyond three months (blue line, intervention group) vs. CAD patients who followed a 3-month CR program only (red line, comparison group, hazard ratio (HR): 2.31 (95% CI=1.42-3.76)).

**Figure 1**

